---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-016569"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2022-12-15T23:59:59+00:00"
generated_at: "2026-06-21T04:21:03.460863+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata receives Nasdaq extension to June 12, 2023 to regain $1 bid price compliance

## Summary
- Nasdaq granted extra 180 days (to June 12, 2023) to meet minimum $1.00 bid price per share.
- Company previously received June 17, 2022 notice; initial 180-day grace period expired Dec 14, 2022.
- May consider a reverse stock split to regain compliance if needed.
- If compliance not regained by June 12, 2023, Nasdaq will start delisting proceedings.
- Delisting risk could adversely affect liquidity, financing ability, and stock price.

## SEC filing metadata
- accession: 0001654954-22-016569
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2022-12-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495422016569/0001654954-22-016569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495422016569/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-016569
- JSON: https://secwatch.observer/filing/0001654954-22-016569.json
- Plain text: https://secwatch.observer/filing/0001654954-22-016569.txt

## Key facts
- Listing & Compliance Notices
  Dermata Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 15, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495422016569/0001654954-22-016569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.